Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights
Tectonic Therapeutic reported Q2 2026 financial results, highlighted by the completion of enrollment in the Phase 2 APEX trial for TX45 in PH-HFpEF patients. The Independent Data Monitoring Committee recommended continuing the study without modification, with topline data anticipated in early Q1 2027.
Key figures
- Net loss
- $22.3 million
- Cash runway
- Q1 2029
- Ga expenses
- $6.2 million
- Rd expenses
- $18.0 million
- Atm proceeds
- $11.7 million
- Cash equivalents
- $227.1 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.